Long Shortz with Aroa Biosurgery: ARX shears first profit in FY25

Aroa Biosurgery releases full year FY25 results, up from the previous financial year, with strong Myriad revenue growth.

Tylah Tully chats with Aroa Biosurgery (ASX:ARX) founder and CEO Brian Ward on the company's FY25 results, posting its first profit since listing on the ASX in 2020. 

The company had a strong year, reporting total revenue of NZ$84.7 million, 23% growth on FY24.

In particular, Myriad™ notched just over NZ$32 million in product revenue, 38% growth on the previous financial year.

Watch the video to hear Ward's insights.

This video was developed in collaboration with Aroa Biosurgery, a Stockhead client at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.